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Abstract
Tissue regenerative gene therapy requires expression 
strategies that deliver therapeutic effective amounts of 
transgenes. As physiological expression patterns are more 
complex than high-level expression of a singular therapeutic 
gene, we aimed at constitutive or inducible co-expression 
of 2 transgenes simultaneously.
 Co-expression of human bone morphogenetic protein 
2 and 7 (BMP2/7) from constitutively expressing and 
doxycycline inducible plasmids was evaluated in vitro 
in C2C12 cells with osteocalcin reporter gene assays 
and standard assays for osteogenic differentiation. The 
constitutive systems were additionally tested in an in vivo 
pilot for ectopic bone formation after repeated naked DNA 
injection to murine muscle tissue.
 Inductor controlled differentiation was demonstrated 
in vitro for inducible co-expression. Both co-expression 
systems, inducible and constitutive, achieved significantly 
better osteogenic differentiation than single factor 
expression. The potency of the constitutive co-expression 
systems was dependent on relative expression cassette 
topology. In vivo, ectopic bone formation was demonstrated 
in 6/13 animals (46 % bone formation efficacy) at days 14 
and 28 in hind limb muscles as proven by in vivo µCT and 
histological evaluation. 
 In vitro findings demonstrated that the devised single 
vector BMP2/7 co-expression strategy mediates superior 
osteoinduction, can be applied in an inductor controlled 
fashion and that its efficiency is dependent on expression 
cassette topology. In vivo results indicate that co-expression 
of BMP2/7 applied by non-viral naked DNA gene transfer 
effectively mediates bone formation without the application 
of biomaterials, cells or recombinant growth factors, 
offering a promising alternative to current treatment 
strategies with potential for clinical translation in the future.
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non-viral gene therapy; inducible, BMP2/7; heterodimer; 
intramuscular.
*Address for correspondence:
Georg A. Feichtinger,
Ludwig Boltzmann Institute for Experimental
and Clinical Traumatology,
Donaueschingenstrasse 13,
A-1200 Vienna, Austria
Telephone Number:  +43 1 33110 461
FAX Number: +43 1 33110 460
Email: georg.feichtinger@trauma.lbg.ac.at
Introduction
Transient somatic gene transfer, enabling temporally and 
spatially restricted, safe expression of transgenes in vivo, 
could revolutionise the clinical treatment of organ and 
tissue specific diseases. Current gene transfer methods are 
divided into viral (high efficiency, high immunogenicity) 
and non-viral (low efficiency, low immunogenicity) gene 
transfer for transient expression of therapeutic transgenes 
(Gelehrter et al., 1998; Bleiziffer et al., 2007). Transient 
gene therapeutics can augment local levels of cytokines 
and morphogens to compensate for pathologically down-
regulated gene expression or locally augment growth 
factors to therapeutic levels. In contrast to the therapy 
of monogenetic diseases with stable integrating viral 
vectors, that have to provide life-long stable expression 
of therapeutic genes, non-viral non-integrating vectors 
– such as plasmid DNA – are active as non-replicating 
episomal entities in vivo. The information is lost within a 
specific time frame, with a very rare frequency of random 
chromosomal integration (Martin et al., 1999; Ledwith et 
al., 2000; Coelho-Castelo et al., 2006) and is therefore not 
associated with vector-associated genotoxicity.
 For tissue regenerative gene therapy approaches, the 
inherent drawback of loss of transgene expression in 
transient gene therapy is actually a desired safety feature. 
Temporally regulated, or restricted expression, of the 
therapeutic is mandatory to prevent systemic effects, 
aberrant cellular growth and to allow complex tissue 
growth (Franceschi, 2005; Bleiziffer et al., 2007). Plasmid 
DNA is cleared relatively quickly from the system and does 
not show substantial systemic spread or ectopic expression 
at off-target sites (Hengge et al., 2001; Hohlweg and 
Doerfler, 2001; Gehl, 2003; Coelho-Castelo et al., 2006). 
Low production costs of the non-viral plasmid therapeutic 
are another potential advantage (Bleiziffer et al., 2007). 
Plasmid DNA is produced with sufficient purity and in 
sufficient amounts for clinical application at relatively low 
cost, compared to recombinant growth factors (Bonadio et 
al., 1999; Johnson and Urist, 2000; Tepper and Mehrara, 
2002; Einhorn, 2003) as advanced therapeutics. Gene 
therapeutics lead to an inherent sustained release of 
expressed therapeutic genes by host cells in situ, which 
is more effective due to higher bioactivity of the host-
produced growth factor (Bonadio et al., 1999; Bleiziffer 
et al., 2007). Plasmid DNA has been successfully applied 
in direct in vivo gene transfer for wound healing and 
angiogenesis (Michlits et al., 2007; Mittermayr et al., 
2008), cardiac regeneration (Sundararaman et al., 2011) 
and musculoskeletal regeneration (Grossin et al., 2003; 
Kawai et al., 2006; Osawa et al., 2009; Osawa et al., 
2010).
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 Taking these advantages into account, non-viral vectors, 
such as plasmid DNA, are considered the most likely 
candidates for clinical translation of tissue regenerative 
gene therapies.
 The major drawback of non-viral vectors, however, 
is their low transfection efficacy if used without adjuvant 
measures (naked) (Herweijer and Wolff, 2003; Schertzer et 
al., 2006). A wide range of agents, materials and physical 
methods to enhance the in vivo transfer of plasmid DNA 
have been developed with varying success (Bleiziffer et al., 
2007). An alternative strategy to increase the therapeutic 
effectiveness is plasmid modification (Tolmachov, 
2009; Tolmachov, 2011) and the selection of an optimal 
therapeutic gene to compensate for the low transfection 
efficacy of plasmid vectors in vivo. Furthermore, gene 
combinations are beneficial in experimental models (Zhu 
et al., 2004; Kawai et al., 2006; Steinert et al., 2009; Wan 
et al., 2012). Several multi-gene approaches have already 
been applied for tissue regenerative therapies. In bone 
regeneration it has been shown that combinatorial gene 
therapy using multiple bone morphogenetic protein (BMP) 
genes – especially the combination of BMP2 and BMP7 – 
leads to higher osteogenic bioactivity compared to single 
factor expression (Zhu et al., 2004; Kawai et al., 2006). 
This BMP2/7 co-expression strategy has been shown to 
lead to the expression of a heterodimeric growth factor 
with higher bioactivity (Israel et al., 1996) compared to 
the respective single gene derived homodimeric variants 
(Kawai et al., 2009).
 Gene combinations can be co-delivered as a mixture 
of different single expression cassette plasmids, as 
co-expression plasmids with multiple independent 
transcriptional entities (Kawai et al., 2009) and as plasmids 
encoding poly-cistronic mRNA with intra-ribosomal 
entry sites (IRES) (Gurtu et al., 1996; Guo-ping et al., 
2010). Multi-cistronic plasmids allow the co-expression 
of multiple factors from the same plasmid molecule via 
bidirectional, or separated unidirectional, gene expression 
cassettes and enable the simultaneous expression of 
multiple therapeutic genes at the target site.
 The achievable functional expression levels of 
multi-cassette co-expression systems could be strongly 
related to expression cassette topology, due to potential 
transcriptional interference phenomena (Callen et al., 2004; 
Shearwin et al., 2005) between the promoters. Furthermore, 
multiple expression cassettes using the same heterologous 
promoters could be prone to competitive effects, reducing 
total transgene expression (Ngo et al., 1993). Nevertheless, 
at least within the scope of the co-delivery of 2 therapeutic 
genes, single molecule transcriptional entities can still 
be advantageous in vivo. If both transgenes are encoded 
on the same molecule, then the correlated expression of 
both factors obtained from co-expression plasmid transfer 
should theoretically be higher compared to co-transfection 
of 2 individual plasmids. This correlated co-expression 
from one single molecule can be advantageous for the 
production of heterodimeric growth factor variants (Kawai 
et al., 2009) or for balanced co-expression of 2 individual 
synergetic factors (Banfi et al., 2012).
 Besides constitutive expression strategies, there are 
plasmid systems available with response elements that 
enable regulated, inductor controlled levels of therapeutic 
gene expression. Such, particular regulated expression 
kinetics could provide enhanced safety (on/off inductor 
dependence) and allow mimicking of physiological 
gene expression patterns for increased therapeutic 
efficacy. Systems such as the dual-component (activator 
and response plasmid) tetracycline (Tet) inducible or 
repressed (TetON, TetOFF) regulated gene expression 
systems (Gossen and Bujard, 1992; Gossen et al., 1995; 
Goverdhana et al., 2005) can be applied for this purpose, 
even for co-expression of 2 therapeutic genes (Baron, 
1995).
 For therapeutic in vivo over-expression studies, the 
tetracycline-inducible system (TetON) appears to be more 
suitable than the tetracycline repressible TetOFF system, 
since the TetON system is induced by application rather 
than withdrawal of a small molecule and in a default off-
state in its absence.
 These inducible systems could help to determine the 
minimally required gene dose and to fine-tune therapeutic 
expression levels in experimental models. However, their 
translatability to the clinic remains questionable given the 
complexity of such systems and the need to additionally 
express a heterologous transactivator transgene with 
potential immunogenicity (Le Guiner et al., 2007). Simple 
constitutive co-expression systems, ideally backbone-
devoid minicircle (Chen et al., 2003) variants, on the other 
hand are more likely to be clinically translated.
 With regards to the above mentioned opportunities to 
enhance the therapeutic efficacy of non-viral plasmid based 
gene delivery through modification of the vector, it was 
the aim of this study to design and evaluate constitutive 
and inductor-controlled inducible BMP2/7 co-expression 
plasmids for osteoinductive non-viral in vivo gene therapy. 
The TetON-inducible bidirectional co-expression system 
was modified to contain all elements (response and 
activator sequences) on one single plasmid. Subsequently 
it was evaluated for its inductor dose dependent expression 
kinetics. Its osteoinductive capacity was compared to 
single factor expression, constitutive co-expression or 
application of recombinant growth factors in vitro. The 
constitutive systems were designed based on the plasmid 
backbone pVAX1, which is compliant with FDA safety 
guidelines for plasmid DNA vaccines (FDA Docket No. 
96N-0400), and the employed therapeutic BMP 2 and 
7 cDNAs were of human origin, in order to generate 
constitutive systems with potential for clinical translation. 
These “preclinical” constitutive systems were evaluated in 
vitro for their osteoinductive capacity and tested in vivo in 
an ectopic bone formation assay using repeated non-viral 
intramuscular in vivo gene transfer.
Materials and Methods
Primers
All primers (Table 1) were ordered from Microsynth 
(Balgach, Switzerland).
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Growth factors
Recombinant CHO-derived human BMP-2 was purchased 
from Medtronic Biopharma (Neuchatel, Switzerland, 
PZN#20238). Recombinant CHO-derived human BMP7 
and E. coli-derived BMP-2/7 heterodimer were purchased 
from R&D Systems (Minneapolis, MN, USA, #354-BP, 
#3229-BM). The lyophilised growth factors were dissolved 
according to manufacturers’ instructions and then diluted to 
working stocks 100 ng/µL and stored at -80 °C prior to use.
Plasmids
The constitutive expression plasmid pVAX1 was purchased 
from Life Technologies (Paisley, UK, #V260-20). The 
two-component tetracycline (Tet) inducible co-expression 
system, consisting of the pTREtight-BI response and the 
pTetON-Advanced activator plasmid, was purchased 
from Takara Bio Europe/Clontech (Saint-Germain-en-
Laye, France, #631068, #631069). The click beetle 
luciferase (CBR) plasmid pCBR-Control was purchased 
from Promega (Madison, WI, USA, #E1421). The CMV-
enhanced osteocalcin reporter plasmid pCMVE/mOCP-
EYFPHis was described previously (Feichtinger et al., 
2010). All plasmids were maintained in E.coli TOP10 (Life 
Technologies #C404003) unless indicated otherwise and 
prepared as endotoxin-free maxipreps using the EndoFree 
Plasmid Maxi or Giga kits from Qiagen (Hilden, Germany, 
#12362) for in vitro and in vivo use.
Cloning of human BMP2 and BMP7 cDNAs
Full-length human BMP2 and BMP7 cDNA were cloned 
from human total lung RNA or kidney RNA (Takara Bio 
Europe/Clontech, #636524, #636529) using AMV based 
reverse transcription of poly-a RNA to cDNA (Promega, 
#M5108) according to manufacturers’ instructions and 
primers in Table1. Both cDNAs were subcloned and 
verified into pVAX1 by means of sequencing (Microsynth, 
data not shown).
Preparation of constitutive co-expression plasmids
The co-expression plasmids pVAX1-BMP2/7+ (tandem 
organisation of expression cassettes, Fig. 1C) and pVAX1-
BMP2/7– (divergent organisation of expression cassettes, 
Fig. 1D) were constructed by transferring the complete 
expression cassette for BMP7 expression from pVAX1-
BMP7 to pVAX1-BMP2 (Fig. 1A, restriction sites for 
insertion marked with red lines) to the BspH1 backbone 
site in pVAX1-BMP2 using standard PCR (primers see 
Table 1) and cloning procedures.
Preparation of inducible single-vector co-expression 
plasmids
An inducible expression kinetics reporter system was 
designed by PCR-amplification and cloning of dsRed 
and EYFP in pTREtight-BI using standard cloning 
procedures. This response plasmid pTRE-EYFP/dsRed 
(Fig. 2A) was then modified to a single-vector inducible 
system by cloning the entire reverse tet-transactivator 
(rtTA) expression cassette, obtained through high-fidelity 
Phusion® polymerase (New England Biolabs, Frankfurt, 
Germany, #M0530S) PCR amplification (primers see Table 
1), from the pTetON Advanced activator plasmid (Fig. 
2B) into the BspLU11I site of pTRE-EYFP/dsRed (Fig. 
2A, insertion site marked red) to form pTetON-EYFP/
dsRed (Fig. 2C). Both plasmids were used for expression 
kinetics studies and for a comparison of single vector 
TetON systems with standard double vector systems. The 
therapeutic inducible co-expression plasmid pTetON-
BMP7/2 (Fig. 2D) was created by transferring the cDNAs 
of human BMP2 and human BMP7 into pTREtight-BI 
using standard cloning procedures in the E. coli cloning 
Primer Name Sequence (5’ to 3’) Purpose
hBMP2fls GCCACCATGGTGGCCGGGACCCGCTGT BMP2 cloning
hBMP2flas CTAGCGACACCCACAACCCTC  
hBMP7fls GGGAAGCTTGCCACCGCGATGCACGTGGCG BMP7 cloning
hBMP7flas TTTGCGGCCGCTGCTGCTCATGTTTCCTAATA  
TetONBsp-F TACACATGTGGCACATGTCCAACATTACCGCCATGTTGAC rtTA cloning
TetONBsp-R GCAACATGTTTGGTCGAGCTGATACTTCCCGTCC  
TREtighBspOUT CTGGCCTTTTGCTGGCCTTTTGC single system 
TREtightBspIN CAGAATCAGGGGATAACGCAGG PCR mapping
hBMP7NdeIs TACCATATG GCCACCATGCACGTGCGCTCACTGCGAGC BMP7 subcloning
hBMP7BglIIas AGATCTCTAGTGGCAGCCACAGGCCCGGACCACC to pTREtight-BI-MCSII
NheIdsRed sense TAC GCTAGC GCCACCATGGCCTCCTCCGAGG BMP7 subcloning
HindIIISTOP dsR as AAGCTTCTATTACAGGAACAGGTGGTGGCGGCC to pTREtight-BI-MCSI
pVAXBIas ACATGTCGATGTACGGGCCAGATATACGC BMP7 casette subcloning
pVAXBIs ACATGTGTTCGCTTGCTGTCCATAAAACC in pVAX1-BMP2
pVAXBspIN GAAATGTGCGCGGAACCCCTATTTG pVAX-BMP2/7 PCR mapping
pVAXBspOUT CTGACGCTCAGTGGAACGAAAACTC  
   
qHPRT_as TGGCCTCCCATCTCCTTCAT qPCR for HPRT transcript
qHPRT_s AGTCCCAGCGTCGTGATTAG  
qOC2_as CTGCTTGGACATGAAGGCTTTG qPCR for osteocalcin transcript
qOC2_s GAACAGACAAGTCCCACACAG  
Table 1. List of primers.
169 www.ecmjournal.org
GA Feichtinger et al.                                                                                             Non-viral osteoinductive gene therapy
strain SURE2 (Stratagene/Agilent Technologies, Santa 
Clara, CA, USA, #200152). The system was then modified 
to a single-vector inducible system as described for the 
kinetics reporter system.
Cell culture and transfection
The mouse cell line C2C12, capable of osteogenic 
differentiation (Katagiri T, 1997; Katagiri T, 1994) was 
purchased from the German Collection of Microorganisms 
and Cell Cultures (DSMZ, Braunschweig, Germany, 
#ACC565) and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Sigma-Aldrich, Vienna, Austria, 
#D6546) containing 4.5 g/L D-glucose, supplemented 
with 2 mM L-glutamine (Sigma-Aldrich, #G6392) and 
5 % foetal bovine serum (FBS; Lonza, Basel, Switzerland, 
#14-502E).
 The cells were kept sub-confluent during expansion 
and seeded at 0.5 x 105 cells/mL/well in 24-well plates 
to enable transfection at approx. 80 % confluence unless 
otherwise stated. Differentiation experiments were carried 
out in serum-reduced DMEM+ 1 % FCS for 6 d.
Constitutive systems
Initial transfection studies were carried out in C2C12 
cells at a cell density of 0.5 x 105 cells/mL for 6 d using 
Lipofectamine 2000 (LifeTechnologies, #11668019), 
according to the manufacturer’s instructions. 2 µg total 
pDNA : 2 µL Lipofectamine 2000 per well in a 24-well 
plate was used in transfections with vectors expressing 
only one factor. 1 µg: 1 µg (2 µg total pDNA) of these 
plasmids were used in co-transfection incubated with 
2 µL Lipofectamine 2000. Co-expression plasmids were 
transfected at an amount of 2 µg: 2 µL of Lipofectamine 
2000.
 The constitutive systems were tested with the 
osteocalcin reporter plasmid pCMVE/mOCP-EYFPHis, 
in a super-transfection experiment. C2C12 cells were 
transfected with the reporter plasmid 24 h prior to 
seeding in a T175 flask at 80 % confluence. 24 h post 
transfection with the reporter, the cells were seeded into 
24-well plates at a density of 0.5 x 105 cells/ml. 24 h post 
seeding the cells were super-transfected with 1 µg/well 
of the constitutive pVAX1 over-expression plasmids, and 
Fig. 1. Constitutive Expression Plasmids used in this study. (A-D): BMP2 expression plasmid pVAX1-BMP2 (A), 
BMP7 expression plasmid pVAX1-BMP7 (B), BMP2/7 co-expression plasmid with BMP7 cassette in tandem 
orientation, pVAX1-BMP2/7+ (C), BMP2/7 co-expression plasmid with BMP7 cassette in inverted orientation, 
pVAX1-BMP2/7-. BMP2 cDNA sequence (green), BMP7 cDNA (sequence (yellow), CMV-promoter (CMVp, 
black arrow), bovine growth hormone poly-adenylation signal (BGHpA, black box), pUC origin of replication (pUC 
ori, black box), Kanamycine resistance gene (KanR, white arrow). Target BspH1 target sites for transfer of BMP7 
cassette into pVAX1-BMP2 and borders of integrated cassette marked in red.
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following transfection, the medium was changed to DMEM 
with a reduced serum amount of 1 % FCS. Fluorescence 
microscopy for osteocalcin-linked EYFP expression was 
carried out 6 d post expression vector transfection.
Inducible systems
The expression levels of the inducible reporter systems 
pTRE-EYFP/dsRed, pTetON-Advanced (double vector 
system) and pTetON-EYFP/dsRed were compared by 
fluorescence microscopy after transfection and induction in 
C2C12 cells. The double vector system was co-transfected 
as 1 µg pTRE-EYFP/dsRed response plasmid combined 
with 1 µg of pTetON-Advanced activator plasmid using 
2 µL of Lipofectamine 2000 per well in a 24-well plate. In 
the other group, 2 µg of the single vector system pTetON-
EYFP/dsRed was transfected using 2 µL Lipofectamine 
2000 per well in a 24-well plate.
 Both systems were induced with a single dose 
of doxycycline (0 ng, 250 ng and 1000 ng/mL/well) 
(Takara Bio Europe/Clontech, #631311) at the start of 
the experiment (following transfection) and expression 
of the fluorescent reporter genes was compared 48 h post 
induction. The expression kinetics of the single vector 
system were investigated after transfection into C2C12 
cells and induction with a single dose of 0 ng, 250 ng 
and 1000 ng/mL/well of doxycycline for up to 14 d with 
fluorescence microscopy.
 The therapeutic single vector co-expression system 
pTetON-BMP2/7 was transfected into C2C12 cells to 
test its osteoinductive capacity. Cells were incubated 
with a single dose 0 ng, 250 ng and 1000 ng/mL/well 
of doxycycline and the cells were cultivated for 6 d 
in DMEM+1FCS prior to assessment of osteogenic 
differentiation by microscopy, ALP assays and qPCR.
Fig. 2. Inducible Expression Plasmids used in this study. (A-D): Dual component vector system (A, B): Response 
co-expression plasmid pTRE-EYFP/dsRed (A) and activator plasmid pTetON-Advanced (B). Single component 
vector systems: Response/activator EYFP/dsRed co-expression plasmid pTetON-EYFP/dsRed (C), Response/
activator BMP2/7 co-expression plasmid pTetON-BMP2/7 (D). EYFP cDNA (green), dsRed cDNA (red), Tet response 
element (TRE, light blue box), minimal bidirectional CMV promoters (blue arrows), reverse tet-transactivator (rtTA) 
expression cassette (light blue elements): CMV promoter (CMVp), rtTA cDNA (rtTA), bovine growth hormone 
poly adenylation signal (BGHpA), ColE1 E.coli origin of replication (ColE1, black box), Simian virus 40 (SV40) 
promoter (SV40p, white arrow), SV40 poly-adenylation signal (SV40pA, black box), ampicillin resistance gene 
(AmpR, white arrow), neomycin resistance cassette (NeoR, black arrow). BspLU11I target site for rtTA expression 
cassette transfer into pTRE-EYFP/dsRed (analogue site exists in pTRE-BMP2/7 precursor) and borders of integrated 
cassette depicted in red.
171 www.ecmjournal.org
GA Feichtinger et al.                                                                                             Non-viral osteoinductive gene therapy
 The inducible system was tested with the osteocalcin 
reporter plasmid pCMVE/mOCP-EYFPHis in a co-
culture experiment. 0.25 x 105 pCMVE/mOCP-EYFPHis 
transfected “reporter cells” were mixed with 0.25 x 105 
pTetON-BMP2/7 “osteogenic cells” per well and cultured 
for 6 d in DMEM+ 1 % FCS. Co-Expression of BMP2 and 
BMP7 was induced with a single dose of 0 ng, 250 ng and 
1000 ng/mL/well of doxycycline. Osteocalcin-coupled 
reporter gene expression by pCMVE/mOCP-EYFPHis 
was observed by fluorescence microscopy on day 6.
Alkaline phosphatase (ALP) assay
Enzymatic ALP assays were carried out as previously 
described (Feichtinger et al., 2010). Enzyme activity was 
calculated as fold induction relative to negative control 
samples, 6 d after induction.
Osteocalcin gene expression analysis
Osteocalcin gene expression was determined as fold 
induction (comparative CT method, (Schmittgen and Livak, 
2008)) relative to negative control samples by quantitative 
real-time PCR using SYBR green as previously described 
(Feichtinger et al., 2010) using the primers qOC2_s, 
qOC2_as and qHPRT_s and qHPRTas (Table 1).
BMP-ELISAs
BMP2 and BMP7 concentrations were assessed in samples 
from C2C12 cells transfected with the constitutive 
systems pVAX1-BMP2, pVAX1-BMP7 and pVAX1-
BMP2/7- 24 h after transfection using standard Anti-
BMP2 (BMP-2 Quantikine ELISA Kit, #DBP200, R&D 
Systems/Biomedica, Vienna, Austria) and 7 (Human 
BMP-7 Quantikine ELISA Kit, #DBP700, R&D Systems/
Biomedica, Vienna, Austria) ELISA kits and protocols 
according to the manufacturer’s instructions.
In vivo non-viral naked DNA gene transfer
The animal protocol review board of the City Government 
of Vienna, Austria approved all experimental procedures 
in accordance with the Guide for the Care and Use of 
Laboratory Animals as defined by the National Institute of 
Health. Female nude mice  (Hsd:Athymic Nude-Foxn1nu, 
Harlan Laboratories, Bresso, Italy, #069(nu)/070(nu/+)) 
of approx. 10-12 weeks age weighing approx. 30 g were 
used in this study (n = 18). 
Plasmid Injections
20 µg of either pVAX1-BMP2/7 or pTetON-BMP2/7 
both combined with 20 µg of pCBR plasmid as internal 
luciferase transfection control were injected as a mixture 
(50 µL total) into gastrocnemius hind-limb muscles under 
short inhalation anaesthesia (2 vol.% isoflurane (Forane, 
Abbott GmbH, Vienna, Austria) and 3 L/min air) at each 
day of the treatment protocol. The treatment was repeated 
to a total of 5 injections, resulting in a final total dose 
of 200 µg plasmid DNA per hindlimb muscle (100 µg 
therapeutic plasmid: approx. 3.3 mg/kg therapeutic 
DNA per animal). Tet-inducible BMP2/7 co-expression 
by pTetON-BMP2/7 was induced in vivo using 2 mg 
doxycycline (Takara Bio Europe/Clontech, Saint-Germain-
en-Laye, France, #631311) in 300 mL ringer solution 
(Mayerhofer Pharmazeutika GmbH, Linz, Austria, license 
#16.609) intraperitoneally per day for a total of 7 d.
Micro Computer Tomography (µCT) analysis
In vivo µCT images of hindlimbs were obtained using a 
vivaCT 75 (Scanco Medical, Brütisellen, Switzerland) 
14 and 28 d post last gene transfer under short inhalation 
anaesthesia. Bone volume (mm3) and bone mineral 
density (mg hydroxyapatite per cm3) for 14 and 28 d were 
calculated using Scanco software and a standard density 
calibration phantom.
Bioluminescence imaging
Bioluminescence imaging of CBR luciferase activity after 
in vivo gene transfer was carried out under short inhalation 
anaesthesia 24 h post last plasmid DNA injection using a 
Xenogen IVIS100 Imaging system (Caliper Life Sciences, 
Mainz, Germany). Mice received 0.5 mg D-luciferin 
potassium salt (Caliper Life Sciences, # 122796) in 300 µL 
ringer solution (Mayerhofer Pharmazeutika, Linz, Austria, 
license #16.609) intraperitoneally before imaging. 20 min 
post D-luciferin administration, the mice were imaged for 
2 min. Imaging was carried out at 24 h, 48 h, 72 h, 9 d, 14 d 
and 28 d post last gene transfer. Luminescence intensity 
was depicted in overlay images in false colour.
Histological examination
Gastrocnemius muscles were excised and fixed with 4 % 
paraformaldehyde in PBS for 24 h, dehydrated in 50 % 
ethanol and stored in 70 % ethanol at 4 °C. Samples 
were embedded in paraffin without decalcification, and 
several sections of the same sample were stained with 
haematoxylin and eosin (H&E) and von Kossa staining for 
mineralisation according to standard histology protocols.
Statistical analysis
Results are represented as average ± standard deviation 
(AVG ±SD) unless otherwise stated. Statistical testing 
was carried out using the non-parametric Kruskal-Wallis 
test in conjunction with Dunn’s multiple comparison test 
as post-test for ALP data.
 Real-time PCR data passed normality tests and was 
tested with parametric ANOVA analysis followed by 
Tukey’s multiple comparison test. Bone mineral density 
values for 14 d and 28 d passed normality tests and were 
evaluated with a two-tailed t-test for significance. p < 0.05 
was considered statistically significant (* p < 0.05, *** 
p < 0.001).
Results
Constitutive co-expression systems in vitro
Osteogenic differentiation using single factor expression 
vs. co-expression
The results of the ALP assays did not show any significant 
differences with or without normalisation to DNA content 
in preliminary experiments and were therefore not 
normalised in subsequent experiments in this study.
 ALP assays (Fig. 3.A) showed that the co-transfection 
of 2 individual pVAX1-BMP2 and pVAX1-BMP7 plasmids 
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had the strongest osteoinductive capacity of the tested 
constitutive systems. The co-expression plasmid pVAX1-
BMP2/7- (divergent organisation of expression cassettes, 
Fig. 1D) showed moderate ALP expression (comparable 
to 100 ng/mL recombinant BMP2), significantly elevated 
if compared to the negative control. pVAX1-BMP2/7+ 
(tandem organisation of expression cassettes, Fig. 1C) 
displayed weaker ALP-induction than pVAX1-BMP2/7- 
and failed to induce ALP levels significantly higher 
than the negative control. Single factor expression via 
pVAX1-BMP2 or pVAX1-BMP7 did not induce significant 
up-regulation of ALP compared to the negative control, 
although low-level induction was observable in pVAX1-
BMP2 transfected cells. The strongest induction of ALP 
was achieved in the recombinant growth factor controls 
in which 300 ng/mL recombinant BMP2 homodimer and 
100 ng recombinant BMP2/7 heterodimer were applied. 
No induction of ALP was achieved in samples treated with 
100 ng/mL recombinant human BMP7.
 Osteocalcin reporter transfected C2C12 cells showed 
highest expression of the fluorescent reporter in cultures 
that were super transfected with the constitutive BMP2/7 
co-expression plasmid pVAX1-BMP2/7- (Fig. 4D). 
The cultures furthermore displayed altered morphology 
compared to the negative control. Single factor delivery 
of pVAX1-BMP2 or pVAX1-BMP7 induced detectable 
reporter gene expression at lower EYFP positive cell 
numbers (Figs. 4B,C). The frequency of reporter positive 
cells was slightly higher in BMP2 transfected cells 
compared to BMP7 transfected cells. pVAX1-BMP2 
transfected cells (Fig. 4B) displayed an altered morphology 
compared to the negative control.
Fig. 3. (A)-Enzymatic alkaline phosphatase (ALP) assays of transfected C2C12 cells, 6 days post transfection. 
ALP activation in fold change relative to negative (non-transfected control, n = 10). Constitutive systems: BMP2 
transfected cells (pVAX1-BMP2, n = 4), BMP7 transfected cells (pVAX1-BMP7, n = 4), cells transfected with 
BMP2/7 co-expression plasmid with inverted topology of expression cassettes (pVAX1-BMP2/7+, n = 10), cells 
transfected with BMP2/7 co-expression plasmid with tandem topology of expression cassettes (pVAX1-BMP2/7-, 
n = 10), Co-transfection of 2 individual BMP2 and BMP7 expression plasmids (pVAX1-BMP2+pVAX1-BMP7, 
n = 10). Inducible systems: ALP activity of C2C12 transfected with the inducible BMP2/7 co-expression system 
without doxycycline (pTetON-BMP2/7 0 ng Doxy, n = 4), transfected cells induced with 250 ng/mL doxycycline 
(TetON-BMP2/7 250 ng Doxy, n = 4), transfected cells induced with 1000 ng/mL doxycycline (TetON-BMP2/7 
1000 ng Doxy, n = 15). Recombinant Controls: ALP activity of positive controls stimulated with recombinant human 
BMPs (rhBMP), 100 ng/mL recombinant BMP7 homodimer (100 ng rhBMP7, n = 4), 100 ng/mL recombinant BMP2 
homodimer (100 ng rhBMP2, n = 4), 100 ng/mL recombinant BMP2/7 heterodimer (100 ng rhBMP2/7, n = 4), 
300 ng/mL recombinant human BMP2 homodimer (300 ng rhBMP2, n = 10). Average ±standard error of the mean 
(AVG ±SEM). * p < 0.05, *** p < 0.001. (B)-Anti-BMP2 ELISA and Anti-BMP7 ELISA of transfected C2C12 
samples 24 h post transfection. n = 4, AVG ±SD.
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BMP-ELISAs
Anti-BMP2 and BMP7 ELISAs (Fig. 3B) showed 
production of BMP2 and BMP7 according to the chosen 
single gene expression system. Interestingly, when the 
constitutive BMP2/7 co-expression system pVAX1-
BMP2/7- was evaluated by ELISA, it was possible to 
detect the formation of BMP7 (reduced in comparison to 
single gene expression) but no formation of BMP2 could 
be detected in contrast to single gene expression.
Inducible co-expression systems in vitro
Single vs. double vector TetON co-expression systems
Both Tet-inducible co-expression systems, the two-
component (response + activator plasmid, Figs. 2A,B) and 
the one component (response/activator plasmid, Fig. 2C) 
system, displayed comparable, dose dependent activation 
of the EYFP and dsRed co-expression reporter genes 48 h 
post treatment with a single dose of doxycycline (Fig. 
5 B&E, C&F). Basal expression was absent in inactive 
controls not treated with doxycycline (Fig.5A&D).
 The majority of reporter expressing cells emitted both, 
EYFP and dsRed fluorescence.
TetON co-expression kinetics
Fluorescence imaging of the inducible single vector 
co-expression plasmid pTetON-EYFP/dsRed for 10 d 
Fig. 4. Fluorescence microscopy based pCMVE/mOCP-EYFPHis osteocalcin reporter gene assay with
constitutive co-expression systems. Transiently transfected osteocalcin reporter cells without supertransfection 
(A), pVAX1-BMP2 supertransfected, BMP2 expressing reporter cells (B), pVAX1-BMP7 supertransfected, BMP7 
expressing reporter cells (C), pVAX1-BMP2/7- supertransfected, BMP2/7 co-expressing reporter cells. Scale bars 
represent 200 µm.
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Fig. 5. Inducible EYFP/dsRed co-expression systems. Fluorescence microscopy of EYFP/dsRed expression of the dual 
component TetON system pTRE-EYFP/dsRed+pTetON-Advanced (A-C) and the single component response/activator 
EYFP/dsRed coexpression system pTetON-EYFP/dsRed (D-F). Scale bars represent 200μm.
Fig. 6. Fluorescence microscopy of EYFP/dsRed co-expression kinetics of the response/activator EYFP/dsRed co-
expression system pTetON-EYFP/dsRed after application of a single dose of doxycycline (Doxy), 0 ng/mL Doxy 
control (0 ng Doxy/mL), 250 ng/mL Doxy induction (250 ng Doxy/mL), 1000 ng/mL Doxy induction (1000 ng Doxy/
mL). Scale bars represent 200 µm.
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revealed doxycycline dose dependent expression kinetics 
(Fig. 6). Expression was observable as early as 12 h 
post administration of 250 ng/mL or 1000 ng/mL of 
doxycycline. A peak of fluorescence positive cells was 
observed at 48 h post administration of a single dose of 
1000 ng/mL doxycycline. After 120 h post administration 
lower numbers of cells were positive and exhibited 
exclusively dsRed fluorescence. This fluorescence 
decreased further on day 10.
 No basal expression of EYFP or dsRed fluorescence 
was detected in control samples not induced with 
doxycycline.
Fig. 7. (A-C) Morphology of C2C12 cells transfected with the inducible response/activator BMP2/7 co-expression 
plasmid (pTetON-BMP2/7), 6 d post transfection. Control cells without doxycycline (A, 0 ng Doxy/mL), cells induced 
with 250 ng/mL doxycycline (B, 250 ng Doxy/mL), cells induced with 1000 ng/mL doxycycline (C, 1000 ng Doxy/
mL). Scale bars represent 200 μm. (D-F): Co-culture experiment with pCMVE/mOCP-EYFPHis osteocalcin reporter 
transfected cells and inducible response/activator BMP2/7 co-expression plasmid (pTetON-BMP2/7) transfected cells 
(1:1). Reporter signal in co-cultures without induction of BMP2/7 co-expression (D, 0 ng Doxy/mL), reporter signal 
in co-cultures after induction with 250 ng/mL doxycycline (E, 250 ng Doxy/mL), reporter signal in co-cultures after 
induction with 1000 ng/mL doxycycline (F, 1000 ng Doxy/mL). Arrowheads mark cell clusters with reporter gene 
expression. Scale bar represents 200 μm. (G) Endogenous osteocalcin expression 6 d after transfection with the inducible 
response/activator BMP2/7 co-expression plasmid (pTetON-BMP2/7). Fold induction of endogenous osteocalcin 
expression depicted as fold changes relative to control cells (no doxycycline addition) normalised to hypoxanthineguanine 
phosphoribosyltransferase housekeeping gene expression. Fold expression in control cells (0 ng DOXY) Fold expression 
after induction with 250 ng/mL doxycycline (250 ng DOXY) and fold expression after induction with 1000 ng/mL 
doxycycline (1000 ng DOXY). n = 6, Average ±standard error or the mean (AVG ±SEM) * p < 0.05, *** p < 0.001.
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Fig. 8. Representative in vivo µ-CTscans of ectopic bone formation at 14 and 28 d after non-viral in vivo gene transfer 
of the constitutive BMP2/7 co-expression plasmid pVAX1-BMP2/7-. Scale bar represents 1 mm. Representative 
luciferase activity as observed by in vivo bioluminescence imaging 24 h post last injection (day 6 post first injection). 
Colour scale represents emitted photons/sec.
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Inducible osteogenic differentiation
Induction of osteogenic differentiation (ALP assays, 
Fig. 3) by BMP2/7 co-expression showed a doxycycline 
dose dependency. Induction with 250 ng/mL doxycycline 
stimulated expression of ALP at levels comparable to cells 
treated with 100 ng/mL recombinant BMP2. 1000 ng/
mL of doxycycline triggered ALP expression to similar 
levels as treatment with 100 ng/mL recombinant BMP2/7 
heterodimer or 300 ng/mL recombinant BMP2 homodimer 
and was significantly higher than the negative control.
 No induction of ALP expression was detectable in 
samples not treated with doxycycline. These findings were 
paralleled by morphologic observations (Fig. 7A-C) that 
revealed changes only in samples treated with 250 ng/mL 
or 1000 ng/mL of doxycycline.
 TetON-BMP2/7 cells co-cultured with osteocalcin 
reporter transfected cells (Fig. 7D-F) induced osteocalcin-
specific fluorescence reporter gene expression upon 
treatment with doxycycline. Fluorescence accumulated in 
cellular clusters of differentiation.
Fig. 9. Bone volume (BV, 
mm3) and Bone mineral 
d e n s i t y  ( B M D ,  m g 
hydroxyapatite/cm3) values 
for ectopic bones, 14 and 
28 d post treatment. Average 
±standard error of the mean 
(AVG ±SEM).
Fig. 10. Histology of ectopic bone in gastrocnemius muscles. Haematoxylin/Eosin (HE) staining (A, B): Muscle tissue 
(M), Bone tissue (B), Bone marrow (BM), Adipocytes (AC), Haematopoiesis is depicted by black arrows (B). Scale 
bars represent 100 µm (A) or 50 µm (B) respectively. Von Kossa staining for mineralisation (C, D): Muscle tissue 
(M), Bone tissue (B), Bone marrow (BM). Nuclei counterstained with haematoxylin (Mayer). Scale bars represent 
100 µm (C) or 50 µm (D) respectively.
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 Endogenous expression of osteocalcin, quantified 
by qPCR, increased significantly in TetON-BMP2/7 
transfected cells upon treatment with increasing doses 
doxycycline (Fig. 7G). A statistically significant, dose 
dependent difference in osteocalcin expression was 
observed between 250 ng and 1000 ng/mL doxycycline. 
Both induced groups exhibited significantly higher 
osteocalcin expression compared to the control without 
doxycycline.
In vivo gene transfer
Bioluminescence monitoring of gene transfer efficacy
Detection of luciferase expression (Fig. 8) 24 h post last 
plasmid injection confirmed gene transfer and expression 
for 8 out of 13 animals (gene transfer efficacy of 61 %) 
treated. Luciferase expression levels were highly variable 
among animals, no specific peak was detected within 
the observed period of 28 d and some animals showed 
luciferase activity for more than 21 d (data not shown).
In vivo µCT Imaging
µCT images of hindlimbs at day 14 and day 28 (Fig. 
8) confirmed ectopic bone formation in gastrocnemius 
muscles after treatment with pVAX1-BMP2/7- for both 
time points in 6 out of 13 animals (46 % bone formation 
efficacy). Furthermore, resorption and remodelling of 
ectopic bones was observable in 28 d images in comparison 
with the 14 d images. The ectopic bones displayed 
varying morphology, ranging from singular structures of 
notable size in some animals to several smaller centres of 
ossification in others. Total bone volumes were variable 
for both time points (14 d: 0.59 ±0.29 mm3; 28 d: 
0.29 ±0.17 mm3). Bone mineral density significantly 
increased from 181.5 ±7.9 mg/cm3 hydroxyapatite (14 d) 
to 229.8 ±17.6 mg/cm3 (28 d) during the observed time 
period (Fig. 9).
 µCT and bioluminescence data were furthermore 
analysed for correlation, given that initial results indicated 
a potential correlation and bone formation was expected to 
correlate with gene transfer efficacy and gene expression 
levels. However, this correlation was not significant.
 No bone formation was observed after treatment with 
pTetON-BMP2/7 and doxycycline in any of the 6 animals 
in the inducible system group.
Histological examination
The formed ectopic bone structures displayed a compact 
layer of bone, including osteocytes and bone synthesising 
lining osteoblasts, haematopoiesis and a bone marrow like 
lumen with progenitor cells and adipose cells observed in 
HE stained samples (Fig. 10A, B). Von Kossa staining for 
mineralisation confirmed ectopic structures as mineralised 
bone tissue (Fig. 10C, D).
Discussion
The study presented herein was aimed at designing and 
evaluating co-expression systems for the constitutive 
and inducible co-delivery of 2 different BMP genes for 
induction of osteogenic differentiation by means of non-
viral gene therapy. Co-expression of BMP2 and BMP7 
has been demonstrated to be more effective than single 
factor expression in vitro. This particular co-expression 
strategy displayed potent osteoinductive capacity, with 
a potency comparable to the application of recombinant 
growth factors in vitro. The potency of the differentiation 
induced by expression from constitutive single molecule 
co-expression plasmids was dependent on expression 
cassette topology and associated potential transcriptional 
interference.
 Furthermore, it was possible to demonstrate the 
feasibility of applying this strategy in an inducible fashion, 
triggering the expression of 2 transgenes simultaneously 
in a doxycycline dependent manner. This system enabled 
tight control of BMP expression and induction of 
differentiation in vitro, being silent in the non-induced 
state. In vivo ectopic evaluation of the constitutive co-
expression system with divergent orientation of expression 
cassettes clearly demonstrated an osteoinductive potential. 
Repeated injection into mouse hind-limb muscles was 
leading to formation of ectopic bone in 46 % of treated 
animals after 5 injections of only 20 µg therapeutic DNA 
per day, displaying similar efficacy at lower daily and 
total doses when compared to approaches  using BMP2 
gene delivery only (Osawa et al., 2010). The inducible 
system in contrast, did not show in vivo ectopic bone 
formation after 5 injections of 20 µg therapeutic DNA per 
day and induction of gene expression for 7 d using 2 mg 
doxycycline i.p. per day, indicating a limiting threshold 
of BMP2/7 co-expression levels required for successful 
induction of bone formation.
In vitro evaluation
Constitutive co-expression systems
Multi-gene approaches, in which more than one therapeutic 
gene is expressed simultaneously, can enhance efficacy 
of gene therapies in vivo. Therefore, a plasmid based 
constitutive co-expression system was investigated for the 
correlated co-delivery of BMP2 and BMP7 genes.
 BMP2/BMP7 co-expression was chosen as a proof 
of concept in this study given its high osteoinductive 
potential in vitro and in vivo (Zhu et al., 2004; Kawai et 
al., 2006; Zheng et al., 2010), which has been shown to 
trigger expression of heterodimeric BMP2/7 (Kawai et 
al., 2009), a growth factor with high bioactivity (Israel 
et al., 1996; Zheng et al., 2010). Higher osteoinductive 
potential of BMP2/7 co-delivery in comparison with 
single gene delivery has been confirmed by ALP assays 
and osteocalcin reporter gene assays in vitro in this work. 
It has been observed that the co-transfection of individual 
BMP2 and BMP7 encoding plasmids leads to a higher 
osteoinductive stimulus in vitro when compared to single 
co-expression plasmid delivery. Lower activity of single 
plasmid co-expression at an even higher dose (1 BMP2 = 1 
BMP7 pmol expression cassettes; 2 µg/well) compared to 
higher activity at a lower dose (0.77 BMP2+ 0.77 BMP7 
pmol expression cassettes; 1 µg + 1 µg/well) of individual 
expression plasmids strongly suggests interference 
phenomena impairing expression in the constitutive CMV-
based co-expression systems.
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 The influence of transcriptional interference phenomena 
(Shearwin et al., 2005) needs to be taken into account when 
working with multiple expression cassettes. CMV-enhancer 
elements were shown to compete for transcription initiation 
complex formation in plasmids, through interference 
of their respective enhancer elements (Andersen et 
al., 2011), which might partially account for the lower 
expression efficacy and osteoinductive potential of both 
constitutive co-expression systems in vitro. However, we 
observed better osteoinduction with the divergent system 
compared to tandem organisation, indicating the presence 
of stronger downstream interference phenomena in the 
tandem configuration. Given the limited predictability of 
transcriptional interference and the potential compound 
effect of multiple forms of transcriptional interference on 
one specific construct, such effects have to be elucidated 
empirically (Curtin et al., 2008) with different cassette 
arrangements as demonstrated in the current study. 
Another potential issue regarding multi-cassette expression 
plasmids is the potential for intramolecular recombination 
(Rubnitz and Subramani, 1985) after transfection of 
plasmids containing direct (tandem) repeated sequences. 
Such recombination events, although expected to be 
relatively rare (Chakrabarti et al., 1985; Chakrabarti and 
Seidman, 1986; Timme et al., 1989) are non-conservative 
(Chakrabarti and Seidman, 1986) and could lead to the 
elimination of sequences from the plasmids. In this 
study this could be the especially the case for the tandem 
constitutive co-expression system pVAX1-BMP2/7+, 
given that such intramolecular recombination events in 
episomal elements have been proven to be more likely in 
direct repeat constructs than in inverted repeat constructs 
(Rubnitz and Subramani, 1985) such as pVAX-BMP2/7-. 
Given the low frequency of recombination, however, the 
authors assume that transcriptional interference might be 
the prevalent reason for reduced efficacy of the multi-
cassette constitutive co-expression systems, eventually 
aggravated by potential non-conservative recombination 
events in the direct (tandem organisation of expression 
cassettes) repeat plasmid.
 Given that BMP-heterodimer formation relies on BMP 
dimerisation within the endoplasmic reticulum of the cell 
(Degnin et al., 2004), co-transfection of a single molecule 
is still preferable, when aiming at heterodimer production 
for maximum bioactivity. Co-transfection efficacy and 
balanced expression of 2 transgenes in vitro has been 
demonstrated to be highly variable (Schwake et al., 2010), 
with only a low number of cells positive for both transgenes 
when using individual plasmids for co-transfection, thus 
indicating a potential advantage of delivering 2 transgenes 
via single vector strategies (Kerrigan et al., 2011).
BMP-ELISAs
BMP-ELISAs for BMP2 and BMP7 production showed 
consistent formation of the respective BMP homodimers 
in single gene expression system transfected C2C12 
cells, but not in cells that were transfected with the 
constitutive co-expression system pVAX1-BMP2/7- for 
BMP2/7 heterodimer formation. It was not possible to 
detect BMP2 in these samples, which could be attributed 
to issues in detecting homodimeric BMPs in samples that 
produce heterodimeric BMP variants. It is not clear how 
selective the respective kits used in this study are in terms 
of detecting only homodimeric variants of BMPs and if the 
epitopes used for detection are conformationally linked to 
homodimeric BMPs. As the used kits are not supposed to 
be extensively cross-reactive with the corresponding BMP 
detected by the other kit used it can be assumed that, at 
least for the BMP2 ELISA kit, there are issues in detecting 
heterodimeric BMPs given that formed molecules represent 
only one half of the target epitope of the ELISA kit.
 Indeed, work by Kaito et al. (Kaito et al., 2013) 
has recently demonstrated that overall detectable BMP 
homodimer levels in BMP2/7 co-transfected cultures 
were markedly reduced (approx. 4x) compared to single 
factor expression, which is basically replicating our 
ELISA results. This might be due to issues in detecting 
heterodimeric BMPs with commercial ELISA kits for 
homodimeric BMP detection. The observed reduction for 
homodimeric BMP7 in BMP2/7 co-transfected cultures 
(see Fig. 3, B lower graph) was approximately 3x. If this 
also was the case for BMP2 levels (Fig. 3, B upper graph), 
BMP2 levels in the BMP2/7 co-transfected cultures might 
as well have dropped below the limit of detection and 
therefore led to a negative result for BMP2 quantification 
in the BMP2/7 co-transfected wells. The development of 
sensitive ELISA kits for heterodimeric BMPs could help 
determining if exclusively heterodimeric or if a mixture of 
homodimeric and heterodimeric BMPs are formed upon 
co-transfection with individual or co-expressing BMP2/7 
plasmid systems.
Inducible co-expression systems
Regulation of therapeutic gene expression levels and 
kinetics allows controlling of optimal dosing and can 
help to mimic physiological gene expression patterns. 
Furthermore, bi-directional inducible systems (Baron 
et al., 1995) can deliver 2 transgenes simultaneously 
under the control of an inducible bidirectional promoter. 
These systems, however, require the co-transfection 
of an activator plasmid, expressing the doxycycline 
responsive transactivator protein required for expression 
from the response plasmid. This situation represents 
another setup, where co-delivery of all transcriptional 
units on the same molecule might offer an advantage 
over simple co-transfection of 2 individual plasmids. 
Therefore, we investigated whether modification of the 
original 2-component system to a single plasmid system 
would substantially alter performance. The comparison of 
fluorescence microscopy images of doxycycline controlled 
co-expression of EYFP and dsRed from the original 
2-component system and the novel single molecule system, 
showed no substantial differences in expression levels 
as well as in background expression without induction. 
This suggests that the novel single molecule TetON co-
expression system performs in a similar way as the original 
system.
 Using fluorescence-microscopy, it was possible to 
demonstrate that EYFP and dsRed fluorescence peaks at 
48 h post administration of doxycycline and fluorescence 
persists for up to 10 d in the case of dsRed. The devised 
single vector TetON system responded to doxycycline 
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with expression of functional fluorescent proteins as 
early as 12 h post induction, a substantial drop of positive 
cells already after 120 h and no basal expression without 
addition of doxycycline. These findings are in line with the 
kinetic data obtained in similar studies (Puttini et al., 2001), 
where maximal expression was obtained with 1000 ng/mL 
doxycycline at 48 h and returned to the off-state within 
36 h. Individual turnover rates of the employed reporter 
genes need to be taken into account for kinetic data and 
indeed it has been shown that Tet-regulated gene expression 
studied with enhanced high turnover reporter constructs 
(Voon et al., 2005) responds even faster (within 4 h) than 
detectable with common reporters.  We therefore conclude, 
according to the mentioned studies and our findings that 
transcriptional activation of Tet-regulated co-expression 
can be very fast within few hours and that gene regulation 
turns effective with a specific delay accountable to mRNA 
half-life, protein maturation time and turnover rate (Voon 
et al., 2005). In our experiments using EYFP (maturation 
time: 8-12 h; half-life: ~24 h, (Clontech protocol PT2040-1, 
Clontech application note 2003)) and dsRed (maturation 
time: 8-12 h; half-life: ~4.5 d, (Verkhusha et al., 2003; 
Mirabella et al., 2004)), kinetics were in the range of 12-
48 h for EYFP and 12-240 h for dsRed. For therapeutic 
regulated co-expression such time windows will have 
to be determined for each individual therapeutic gene 
of interest as expression time windows will depend on 
individual protein half-life & stability as well as individual 
mRNA half-lives of different cloned cDNAs. Therefore, 
the obtained kinetics for EYFP and dsRed only represent 
a rough estimate for the effective therapeutic time window 
of gene-expression.
 Co-delivery of BMP2 and BMP7 with this expression 
strategy enabled tightly inductor controlled expression, 
which lead to subsequent differentiation. The extent of 
osteogenic differentiation, as determined by microscopy, 
ALP assays, osteocalcin reporter gene assay and 
quantitative real-time PCR clearly indicated a direct link 
between doxycycline dose and differentiation outcome. 
1000 ng/mL induced cultures showed the most potent 
osteoinduction of all tested systems in vitro and no 
induction of osteogenic differentiation was observed 
without induction with doxycycline. Tightly regulated 
gene co-expression was observed after transfection of 1 
singular plasmid unit in vitro, narrowing the effective time 
window of BMP2/7 co-expression down to approximately 
4 d for C2C12 cells. This system will provide a useful tool 
in future in vivo studies to demonstrate control over in vivo 
bone formation via doxycycline triggered gene expression 
and to determine minimally required therapeutic BMP-
expression time windows for bone induction.
In vivo gene transfer
Intramuscular gene transfer by naked plasmid injection is 
a method already used for a long time in vivo (Herweijer 
and Wolff, 2003) even clinically (Rauh et al., 2001) and 
muscle tissue is an excellent ectopic environment for 
preliminary bone formation assays (Scott et al., 2012), as 
well as for the generation of transplantable bone in clinical 
applications (Warnke et al., 2004). It has previously been 
shown that repeated non-viral BMP2 gene transfer can 
induce bone formation at ectopic sites in vivo (Osawa et 
al., 2010), with fair efficacy depending on the amount of 
repetitive treatments. BMP2/7 co-delivery has already been 
shown to outperform BMP2 delivery after electroporative 
gene transfer in vivo and is perceived as an ideal gene 
combination for osteoinductive gene therapies ( Zhu et al., 
2004; Zhao et al., 2005; Kawai et al., 2006).
 In line with these studies, we tested how the constitutive 
pVAX1 BMP2/7 co-expression plasmid would perform in 
an in vivo test for ectopic bone formation using passive 
DNA delivery. Ideally, by using this BMP2/7 co-expression 
strategy, we aimed at generating results comparable to the 
work of Osawa et al. at a reduced number of repetitive 
treatments (5 vs. 8) and lower total (100 µg vs. 500 µg) 
and daily DNA dose (20 µg vs. 62.5 µg). Furthermore, 
to enable non-invasive gene expression monitoring, we 
incorporated an internal luciferase control plasmid. The 
bone formation efficacy of 46 % observed in this study is 
within the range of efficacy reported by Osawa et al. for 
repeated BMP2 gene delivery, where 4 injections of 125 µg 
BMP2 DNA led to 57 % and 8 injections of 62.5 µg BMP2 
DNA led to 62 % bone formation. Therefore, we conclude 
that BMP2/7 co-expression in vivo induces bone formation 
at lower DNA doses to a similar extent as BMP2 delivery.
 Furthermore, we observed higher bone formation 
efficacy using BMP2/7 co-expression from a CMV-driven 
plasmid, whereas Osawa et al. (as Kawai et al.) employed 
plasmids using the CMV-enhancer chicken b-actin (CAG)-
promoter (Kawai et al., 2006; Kawai et al., 2009; Osawa 
et al., 2010). The CAG-promoter (Miyazaki et al., 1989; 
Niwa et al., 1991) is a very powerful promoter employed for 
ubiquitous sustained gene expression and does not exhibit 
rapid inactivation as observed for the CMV-promoter 
(Yew, 2005). Furthermore, its activity is especially high 
in muscle cells (a potential target in our study) (Robert et 
al., 2012). Therefore, we hypothesise that gene expression 
levels in those studies were matching levels obtained in 
our study, but due to the CMV-promoter in our constructs 
we potentially did not obtain extended therapeutic gene 
expression windows as in the mentioned papers employing 
the CAG-promoter. This further highlights the higher 
bioactivity of the chosen gene combination, as our less-
powerful expression system was still able to produce higher 
bone formation efficacies and modification of our system to 
replace the CMV promoter by the CAG-promoter – similar 
to the BMP2/7 co-expression system used by Kawai et 
al. (Kawai et al., 2009) – could substantially improve its 
performance. The primary aim of this study, however, was 
to develop a system for potential clinical translation and 
therefore we selected the pVAX system, although plasmids 
containing potentially superior promoters could have been 
used.
 The inducible system did not show any bone formation 
after induction in this study. This could be either due to lack 
of successful induction using the systemic, intraperitoneal 
delivery of doxycycline in this work. This is relatively 
unlikely, as the employed dose is very high and induction 
has been achieved in vivo using oral delivery resulting in 
lower systemic amounts of doxycycline ( Perez et al., 2002; 
Cawthorne et al., 2007) compared to the present study. 
Alternatively, it could be due to the fact that the delivered 
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gene dose is limited due to low gene transfer efficacy 
and therefore not sufficient for crossing the threshold for 
ectopic bone formation within the limited time period of 
7 d. Indeed, it has been possible to show that by improving 
gene delivery efficacy, by using sonoporation (Feichtinger 
et al., 2013) for the delivery of the inducible system, it is 
possible to achieve ectopic bone formation and therefore 
linking the observed results to limited gene transfer efficacy 
in this work rather than to limited induction of the TetON 
system.
 Direct comparison of BMP2 with BMP2/7 co-
expression in vivo by Kawai et al. using intramuscular 
electroporation already clearly demonstrated the higher 
osteoinductive potential of BMP2/7 co-delivery and thus 
supports this interpretation (Kawai et al., 2006) although 
using a more invasive approach to gene delivery than 
applied in the present study.
 Similar results for gene transfer efficacy estimation 
based on luciferase expression (61 % positive, 8/13 
animals) and bone formation (46 %, 6/13 animals) 
demonstrated fair gene transfer efficacies and the feasibility 
of employing an internal luciferase control in gene transfer 
studies. However, if compared to previous unpublished 
single-injection data of only luciferase plasmids from 
our group, the luciferase levels reported here are lower 
than expected after gene transfer in vivo – if co-delivered 
with the therapeutic plasmid. This could indicate that 
competitive effects (Ngo et al., 1993) between two 
independent expression systems (CBR luciferase system 
& BMP2/7 co-expression system) can occur in vivo, thus 
potentially hampering luciferase expression monitoring or 
therapeutic efficacy and this is currently under investigation 
both in vitro and in vivo. The generally high variability of 
luciferase expression and bone volumes among animals 
within this study, however, should be mainly attributed to 
the plethora of parameters that affect passive naked DNA 
intramuscular gene delivery and its variability (Wolff, 
1991; Wolff and Budker, 2005), which are difficult to 
control, especially in a treatment protocol that relies on 
multiple injections per site. Injection volumes and injection 
speed have been shown to influence transgene expression 
in vivo (Andre et al., 2006), potentially through additional 
hydrodynamic poration. This can substantially increase 
DNA uptake, in addition to the postulated default receptor-
mediated endocytosis of DNA in muscle (Satkauskas et al., 
2001) mainly responsible for intramuscular naked DNA 
transfer.
 Another caveat of passive BMP gene transfer is that 
the employed DNA doses are still relatively high (~3 mg/
kg for BMP2/7 up to ~15 mg/kg for BMP2 delivery) and 
that a single injection of BMP-plasmids is not sufficient 
in order to obtain efficient expression for ectopic bone 
formation (Osawa et al. and own unpublished data). 
Therefore, given that passive intramuscular gene transfer is 
difficult to control and still requires multiple treatments, it 
might be of higher practical use to introduce an additional, 
preferably non-invasive physical gene transfer method, 
which has been successfully investigated in another study 
(Feichtinger et al., 2013). Such methods can increase and 
unify global transfection efficacy, while reducing the total 
DNA amount applied. Sonoporation (Zhang et al., 2006; 
Osawa et al., 2009) and electroporation (McMahon and 
Wells, 2004; Kusumanto et al., 2007) are such minimally 
invasive methods employing naked DNA without chemical 
agents that can provide increased transfection efficacy in 
vivo and indeed electroporation has already been used for 
the delivery of BMP2/7 co-expression plasmids in vivo 
(Kawai et al., 2006; Kawai et al., 2009).
 The developed, inducible and constitutive BMP2/7 
co-expression plasmids are useful tools for investigating 
the potential of non-viral gene therapeutics and the results 
obtained with these systems provide further evidence for 
the feasibility of developing co-expression based gene 
therapeutics, paving the way for further preclinical research 
on the performance of BMP2/7 co-expression in orthotopic 
models for functional bone regeneration. Gene transfer 
efficacy, consistency and expression vector design are 
variables critically influencing success of such strategies 
and still require further improvement in future studies in 
order to enable translation of this promising approach for 
clinical application.
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Discussion with Reviewers
R. Porter: While the negative inducible in vivo data are 
now mentioned in the text, why are they not included as 
part of Fig. 8?
Authors: As there was no ectopic bone formation 
observable in these samples the authors omitted the 
inclusion of µCT images, which do not contain ectopic 
bone in order to save space for the more relevant images 
of the constitutive system that do actually contain ectopic 
bone structures of interest to the reader. If needed, the 
images of the inducible system negative result µCT scans 
are available and can be provided by the authors.
M. Anton: Your results suggest that passive gene transfer 
will not be practical for generating therapeutic levels of 
BMP expression. To improve gene transfer efficiency, 
you point to promising physical transfer methods, such as 
electroporation or sonoporation.
 For clinical cases where the transfection target is 
relatively deep, such as injury to a long bone, can these 
physical transfer methods be employed without open 
surgery to circumvent the overlying skeletal muscle? What 
are the principal challenges to their application in bone 
repair and regeneration?
Authors: In principle (using X-ray or Ultrasound Imaging 
guided injection at deep within tissue target sites), it would 
be possible to treat such defects with electroporation or 
sonoporation. Sonoporation, however, would be more 
suitable for this approach as it represents a minimally 
invasive stimulus that can be applied from outside the body 
without the need for insertion of needle electrodes as for 
example in electroporation. Although such devices are still 
in development it would be theoretically possible to limit 
the ultrasound stimulus to a defined point in space deep 
within the tissue at the target site by employing phased-
array focussed or convergent beam devices that target high 
intensity ultrasound at specific sites through constructive 
interference. The main challenges of using either physical 
stimulus (electroporation or sonoporation) will be to limit 
potential tissue damage of surrounding tissues exposed to 
strong electrical fields or difficult to control reflection and 
resonance of ultrasound within the body.
M. Anton: Certain indications from rodent bone healing 
models will not readily translate to the treatment of 
patients. It is very possible that the effective timeframe 
for BMP stimulation is one such indication. Consequently, 
larger animal models (e.g., sheep) may have to be used to 
adjust initial suggestions from rodent models. Can your 
inducible expression system be applied to large animal 
models, and what might be the associated challenges? 
Authors: The inducible expression system could be 
applied to large animal models given that feasible gene 
delivery methods for large animals are available as with any 
expression system. The specific challenge associated with 
the use of a doxycycline inducible system in large animals 
are the higher total amounts of doxycycline that have to be 
administered and is potentially different pharmacokinetics 
in a large animal. 
M. Anton: What reporting alternatives to luciferase might 
be suitable for evaluating gene expression noninvasively 
in these models?
Authors: Luciferases are still the most suitable reporter 
genes for noninvasively monitoring of gene expression 
in vivo. However, anticipating significant advances in 
this area of research, it might be possible in the future 
to establish transgenes suitable for magnetic resonance 
imaging (see Kang and Chung, 2008, additional reference), 
which would be the non-invasive method of choice for in 
vivo imaging of gene expression in large animals.
Additional Reference
 Kang JH, Chung JK (2008) Molecular-genetic imaging 
based on reporter gene expression. J Nucl Med 49 Suppl 
2: 164S-179S.
